These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 15257377)

  • 1. [Multiple sclerosis: potential therapeutic options and update of ongoing studies].
    Wiendl H; Lehmann HC; Hohlfeld R; Hartung HP; Kieseier BC
    Nervenarzt; 2004 Jun; 75(6):536-52. PubMed ID: 15257377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?
    Kappos L; Kuhle J; Gass A; Achtnichts L; Radue EW
    J Neurol; 2004 Sep; 251 Suppl 5():v57-v64. PubMed ID: 15549357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current landscape and unmet needs in multiple sclerosis.
    Markowitz CE
    Am J Manag Care; 2010 Sep; 16(8 Suppl):S211-8. PubMed ID: 20873945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B; Hartung HP
    Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Other immunomodulatory therapies in multiple sclerosis.
    Polman CH
    Baillieres Clin Neurol; 1997 Oct; 6(3):511-24. PubMed ID: 10101587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies.
    Ulzheimer JC; Meuth SG; Bittner S; Kleinschnitz C; Kieseier BC; Wiendl H
    BioDrugs; 2010 Aug; 24(4):249-74. PubMed ID: 20623991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial: Licensing and Use of New Therapies in MS: Where Are We Going?
    Hurwitz B
    Int MS J; 2005 Aug; 12(2):39-41. PubMed ID: 16417813
    [No Abstract]   [Full Text] [Related]  

  • 8. Current and future disease-modifying therapies in multiple sclerosis.
    Lim SY; Constantinescu CS
    Int J Clin Pract; 2010 Apr; 64(5):637-50. PubMed ID: 20456216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A changing treatment landscape for multiple sclerosis: challenges and opportunities.
    Piehl F
    J Intern Med; 2014 Apr; 275(4):364-81. PubMed ID: 24444084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies.
    Wiendl H; Kieseier BC
    Expert Opin Investig Drugs; 2003 Apr; 12(4):689-712. PubMed ID: 12665424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnosis and treatment of multiple sclerosis. Update, 2003].
    Jarius S; Hohlfeld R; Voltz R
    MMW Fortschr Med; 2003 May; 145 Suppl 2():88-91, 93, 95. PubMed ID: 14579493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging therapies in multiple sclerosis.
    Farrell R; Heaney D; Giovannoni G
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):797-816. PubMed ID: 16262563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of neuroprotective and alternative treatment strategies.
    Meuth SG; Bittner S; Ulzheimer JC; Kleinschnitz C; Kieseier BC; Wiendl H
    BioDrugs; 2010 Oct; 24(5):317-30. PubMed ID: 20795753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection and neuroregeneration in multiple sclerosis.
    Stangel M
    J Neurol; 2008 Dec; 255 Suppl 6():77-81. PubMed ID: 19300964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern multiple sclerosis treatment - what is approved, what is on the horizon.
    Pilz G; Wipfler P; Ladurner G; Kraus J
    Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade.
    Van der Walt A; Butzkueven H; Kolbe S; Marriott M; Alexandrou E; Gresle M; Egan G; Kilpatrick T
    Pharmacol Ther; 2010 Apr; 126(1):82-93. PubMed ID: 20122960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the treatment options for multiple sclerosis.
    Niino M; Sasaki H
    Expert Rev Clin Immunol; 2010 Jan; 6(1):77-88. PubMed ID: 20383893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to neuroprotective strategies in multiple sclerosis.
    Tselis A; Khan OA; Lisak RP
    Expert Opin Pharmacother; 2010 Dec; 11(17):2869-78. PubMed ID: 20687779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent clinical trials and future therapies.
    Meuth SG; Kleinschnitz C; Wiendl H
    J Neurol; 2008 Dec; 255 Suppl 6():93-6. PubMed ID: 19300967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple paradigm shifts in multiple sclerosis.
    Kieseier BC; Hartung HP
    Curr Opin Neurol; 2003 Jun; 16(3):247-52. PubMed ID: 12858058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.